CN104293953A - Screening kit for senile macular degeneration diseases - Google Patents
Screening kit for senile macular degeneration diseases Download PDFInfo
- Publication number
- CN104293953A CN104293953A CN201410536200.9A CN201410536200A CN104293953A CN 104293953 A CN104293953 A CN 104293953A CN 201410536200 A CN201410536200 A CN 201410536200A CN 104293953 A CN104293953 A CN 104293953A
- Authority
- CN
- China
- Prior art keywords
- variation
- site
- gene locus
- reagent
- rdbp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012216 screening Methods 0.000 title claims abstract description 12
- 206010064930 age-related macular degeneration Diseases 0.000 title abstract description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 49
- 101000979288 Homo sapiens Negative elongation factor E Proteins 0.000 claims abstract description 32
- 101150050948 SKIV2L gene Proteins 0.000 claims abstract description 31
- 238000001514 detection method Methods 0.000 claims description 26
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 208000002780 macular degeneration Diseases 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000038018 age-related macular disease Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses variation basic groups at SKIV2L gene locus rs429608 and rs2075702 and an RDBP gene locus, rs3880457 and rs9501161. The invention further discloses application of a reagent for detecting the variations of the basic groups in preparation of a screening reagent of the senile macular degeneration diseases, and a screening kit for the senile macular degeneration diseases. The kit can be used for assisted diagnosis of the senile macular degeneration diseases, and resistance assessment of individual senile macular degeneration diseases.
Description
The application is the applying date: on May 4th, 2013, application number: 201310176231.3, denomination of invention: a kind of divisional application of patent application of kit for screening of agedness yellow spot degenerative disease.
Technical field
The present invention relates to SNP field, particularly relevant to age-related macular degeneration SNP.
Background technology
Age-related macular degeneration (age-related macular degeneration, AMD), be considered to a class with the different substantiality disease that Progressive symmetric erythrokeratodermia central vision declines and macula area retinitis pigmentasa is feature, it is one of primary disease of whole world adult's blinding, whole world number of patients 1,000 ten thousand, China 60-69 year crowd AMD morbidity is can reach 15.33% in more than 7.77%, 70 years old.Macular degeneration comprises age-related macular degeneration, macular dystrophy (stargart is sick, best is sick, sorsby fundus dystrophy etc.).
Recent study is thought, macular degeneration is one group of different substantiality disease, and a lot of research shows it and has significant genetic predisposition.At present, susceptibility genetic marker research about agedness yellow spot degenerative disease is more, as, at notification number: in the patent application document of the patent document of 101173314B, 101550451B, publication number: 101857899A, disclose the susceptibility genetic marker of agedness yellow spot degenerative disease and preparing the purposes in agedness yellow spot degenerative disease detection reagent.But, few about the genetics of resistance marker research of agedness yellow spot degenerative disease.
Summary of the invention
In order to solve the problem, the invention provides a kind of kit for screening of new agedness yellow spot degenerative disease.
The invention provides 5 kinds of variation bases, variation base I is A, is positioned at SKIV2L gene locus rs429608; Variation base II is C, is positioned at SKIV2L gene locus rs2075702; Variation base III is C, is positioned at RDBP gene locus rs760070; Variation base III is C, is positioned at RDBP gene locus rs3880457; Variation base III is A, is positioned at RDBP gene locus rs9501161.
SNP is the abbreviation of Single Nucleotide Polymorphism, and translator of Chinese is single nucleotide polymorphism, refers to the variation of single core thuja acid on genome.Aforementioned 5 variation bases belong to the result of single nucleotide variations.
Present invention also offers detection SKIV2L gene locus rs429608 variation, site rs2075702 makes a variation, RDBP gene locus rs760070 makes a variation, site rs3880457 makes a variation or/and the purposes of related reagent in the screening agent preparing agedness yellow spot degenerative disease of site rs9501161 variation.
Wherein, described reagent comprises detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C makes a variation, RDBP gene locus rs760070 makes a variation T → C, site rs3880457T → C variation or/and the reagent of site rs9501161G → A variation; Also comprise optional SKIV2L gene locus rs429608, site rs2075702, RDBP gene locus rs760070, the site rs3880457 of comprising for increasing or/and the reagent of gene fragment of site rs9501161.
Wherein, described detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C variation, RDBP gene locus rs760070 make a variation T → C, site rs3880457T → C variation or/and the reagent that site rs9501161G → A makes a variation is Snapshot reagent.
Wherein, described detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C variation, RDBP gene locus rs760070 make a variation T → C, site rs3880457T → C variation or/and the reagent that site rs9501161G → A makes a variation is order-checking reagent.
Wherein, described detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C makes a variation, RDBP gene locus rs760070 makes a variation T → C, site rs3880457T → C variation or/and reagent restriction fragment length polymorphism method reagent that site rs9501161G → A makes a variation or single-strand conformation polymorphism analysis reagent.
Present invention also offers a kind of kit for screening of agedness yellow spot degenerative disease, it comprises, and optional for detecting, SKIV2L gene locus rs429608 makes a variation, site rs2075702 makes a variation, RDBP gene locus rs760070 makes a variation, site rs3880457 makes a variation or/and related reagent that site rs9501161 makes a variation.
Wherein, it comprises detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C makes a variation, RDBP gene locus rs760070 makes a variation T → C, site rs3880457T → C variation or/and the reagent of site rs9501161G → A variation; Also comprise optional SKIV2L gene locus rs429608, site rs2075702, RDBP gene locus rs760070, the site rs3880457 of comprising for increasing or/and the reagent of gene fragment of site rs9501161.
Preferably, T → C, site rs3880457T → C variation that described detection SKIV2L gene locus rs429608G → A makes a variation, site rs2075702T → C makes a variation, RDBP gene locus rs760070 makes a variation is or/and the reagent that site rs9501161G → A makes a variation is Snapshot reagent.
Preferably, T → C, site rs3880457T → C variation that described detection SKIV2L gene locus rs429608G → A makes a variation, site rs2075702T → C makes a variation, RDBP gene locus rs760070 makes a variation is or/and the reagent that site rs9501161G → A makes a variation is order-checking reagent.
Preferably, T → C, site rs3880457T → C variation that described detection SKIV2L gene locus rs429608G → A makes a variation, site rs2075702T → C makes a variation, RDBP gene locus rs760070 makes a variation is or/and the reagent that site rs9501161G → A makes a variation is restriction fragment length polymorphism method reagent or single-strand conformation polymorphism analysis reagent.
The present invention illustrates SKIV2L gene locus rs429608 variation first, site rs2075702 makes a variation, RDBP gene locus rs760070 makes a variation, site rs3880457 makes a variation or/and the protection type that rs9501161 variation in site is agedness yellow spot degenerative disease makes a variation, and aforementioned variation effectively can reduce the ill probability of agedness yellow spot degenerative disease.Use test kit provided by the invention, can the resistance to agedness yellow spot degenerative disease of effective examination crowd to be checked, assess the possibility that crowd to be checked suffers from age-related macular disease, application prospect is good.
Measuring method of the present invention measures the genomic dna deriving from people, sample does not limit, as body fluid (as blood, ascites and urine), histocyte (as hepatic tissue) etc., all genomic dna can be prepared by these samples of Isolation and purification.
Each base type on chromosomal DNA same position is called a loci, and SNP mostly only has two kinds of allelotypes in crowd, therefore is also called two equipotential mark, and its detection is the detection mode of a kind of "+/ ﹣ " or " complete/nothing ".The detection method of SNP is varied, can be divided into sequencing, hybrid method, dissolution method, electrophoretic method, chemical method, zymetology method, Physical and their combined method, and these methods are all detect the normal experiment means of nucleotide diversity.The invention discloses SKIV2L gene locus rs429608 variation, site rs2075702 makes a variation, RDBP gene locus rs760070 makes a variation, site rs3880457 makes a variation or/and the base type of site rs9501161 variation, and the sequence of SKIV2L gene and RDBP gene is known, the polymorphism in above-mentioned two sites all can be detected by the method for existing detection nucleotide diversity.
Accompanying drawing explanation
Fig. 1 Snapshot detects the gene type collection of illustrative plates in SNP rs429608 site
Fig. 2 Snapshot detects the gene type collection of illustrative plates in SNP rs2075702 site
Fig. 3 Snapshot detects the gene type collection of illustrative plates in SNP rs760070 site
Fig. 4 Snapshot detects the gene type collection of illustrative plates in SNP rs3880457 site
Fig. 5 Snapshot detects the gene type collection of illustrative plates in SNP rs9501161 site
Embodiment
The embodiment of form by the following examples, is described in further detail foregoing of the present invention.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment.All technology realized based on foregoing of the present invention all belong to scope of the present invention.
For representing in the following example that reagent is commercially available product, its english abbreviation is as follows.
When needing, with pressure kettle (120 DEG C, 20 minutes) sterilizing
EDTA: disodium ethylene diamine tetraacetate
SDS: sodium lauryl sulphate
TE：10mM?Tris-HCl(pH7.5)、1mM?EDTA(pH8.0)
DNTP: deoxynucleoside triphosphate
The extraction of embodiment 1 sample collection and genomic dna
Sample is the case that the state natural sciences fund problem (problem number: 30771220,81170882) born by People's Hospital, Sichuan Prov. of Sichuan Academy of Medical Sciences Human disease gene research Key Laboratory of Sichuan Province is collected.Amount to and collect patients with age-related macular degeneration 370 example, 68.7 ± 10.9 years old mean age, wherein the male sex accounts for 199 examples and accounts for 53.8%, and contrast 632 example, 69.4 ± 9.2 years old mean age, wherein the male sex 326 example accounts for 51.6%.All persons under inspection are Han nationality, and signature Informed Consent Form, this research have also been obtained Ethics Committee's approval.
According to following method, prepare genomic dna with human peripheral.Under antithrombotics EDTA exists, the 5ml human peripheral collected is removed serum deprivation in 30 minutes in 3000rpm centrifugation.Then add 0.2%NaCl solution, make cumulative volume be 50ml.Vibration solution 5-6 time gently, and make it be positioned over 15 minutes on ice.After this, at 3000rpm centrifugation 30 minutes, whereby collecting precipitation thing.By the NaCl solution of 0.2%, wash again in a manner similar to before.In the throw out so obtained, add 10mM Tris-HCl (pH8.0) and 10mM EDTA (4m1), with this throw out that suspends.Add in suspension by the Proteinase K of 10%SDS, 25mg/ml and the RNaseA of 10mg/ml, its add-on is respectively 4ml, 16 μ l and 20 μ l, and the suspension that then turns upside down mixes gently.Then, at 37 DEG C of Overnight incubation suspensions.After spending the night, add 4ml phenol/Tris solution, the mixture of the mixture mixing gained that turns upside down.With 3000rpm centrifugation 10 minutes removing water layers.By water layer and 4ml phenol/chloroformic solution mixing, then against mixing and with 3000rpm centrifugation 10 minutes, removing water layer.Finally, with chloroform extraction twice, to obtain aqueous phase, toward wherein adding l/10,3M NaAC (pH5.2), the cold dehydrated alcohol of doubling dose, makes DNA precipitate.Washing with alcohol with 70% is to obtain genomic dna.Finally be dissolved in TE by the genomic dna of gained, then quantitative assay mixture is in the specific absorption of 260nm, and DNA working fluid concentration correction, to 50ng/ μ l, puts-20 DEG C of Refrigerator stores.
Embodiment 2 comprises pcr amplification and the gene type assay of rs429608, rs2075702, rs760070, rs3880457 and rs9501161 single nucleotide polymorphism DNA fragmentation
The present invention adopts Snapshot genotyping technique to detect rs429608, rs2075702, rs760070, rs3880457 and rs9501161 five sites.Gene amplification reagent and Snapshot primer A-E is adopted to carry out somatotype by the following method respectively.
Experimental procedure is as follows:
1, PCR:95 DEG C of sex change 5 minutes; 95 DEG C 30 seconds, 55 DEG C annealing, 30 seconds, 72 DEG C extensions 45 seconds, 35 circulations; 72 DEG C extend 7 minutes, 4 DEG C of insulations.
2, purifying 1:PCR product is respectively got 1-3 μ l (determine according to the PCR number that need mix, total amount is 9 μ l, adds mixed solution 3 μ l (SAP 2 μ l, 1:10Exol enzyme 1 μ l).The preparation of 1:10Exol enzyme: 1 volume Exol enzyme, 1 volume SAP 10Xbuffer, 8 volume ddH2O.Program: 37 DEG C of 1h, 75 DEG C of 15min.
3, Snapshot reaction: Snapshot MULTIPLEX 1 μ l, purified PCR mix 1 μ l, Snapshot primer is each is that 0.2 μ l, DDH2O supply 5 μ l.Program: 96 DEG C 1 minute, 96 DEG C 10 seconds, 50 DEG C 5 seconds, 60 DEG C 30 seconds, cycle to step 2for 25more times, 12 DEG C of insulations.
4, purifying 2: each reaction adds SAP 0.5-1.0 μ l, program: 37 DEG C 1 hour, 75 DEG C 15 minutes, 4 DEG C of insulations.
5, the above-mentioned product of 1 μ l adds 9 μ l HD.Program: 95 DEG C, 5 minutes, puts rapidly on ice, upper machine testing after cooling.
PCR primer pair A (rs429608):
F:5’-GTAAGGGCAGTTTGGGTGAA-3’
R:5’-GAGCCACTGTACAGCATGGA-3’
PCR primer pair B (rs2075702):
F:5’-GCTGAGATGTGTCGCTCACT-3’
R:5’-GACTCAGGACCTCCCATCAC-3’
PCR primer pair C (rs760070):
F:5’-TGGATGTCTGCAAAAACCAG-3’
R:5’-CTGGATTCCTTGTGCCTCAT-3’
PCR primer pair D (rs3880457):
F:5’-ATGAGGCACAAGGAATCCAG-3’
R:5’-GGTTGGCACAAAGGAGCTAA-3’
PCR primer pair E (rs9501161):
F:5’-CCATCCCTTAGGGCAACATA-3’
R:5’-ACACAGCCACAGCAACAGAG-3’
The extension increasing sequence obtained is as follows:
Sequence 1 (rs429608) 429bp:
GTAAGGGCAGTTTGGGTGAAgaagaggagcacctgagcttctggggcatgcttccacgagggctccatgtgggagaggaagtgcgggccatgagtctgcggagggactggctaacttcatgctctcttcccagcaccatctacacttcgcccatcaaggccctgagcaaccagaagttccgggacttccgaaacacattcggggatgtggggctgctcaccggggatgtacagctgcatccggaggcctcctgcctcatcatgaccacagagatccttcggtgagagatggacactcaatacaggggagttttggctgggaagatgtggccgttgtggagagtgtgctgtctgaggagggggtggagacgagccactggG/AgagtcaatccttggcctcttctccccagcTCCATGCTGTACAGTGGCTC
Sequence 2 (rs2075702) 339bp:
GCTGAGATGTGTCGCTCACTgcggggggcagcccgcctggtaggagagcctgtgctgggtgccaagatggagacagcggctaccttgctacggcgggacatcgtatttgcggccagcctctacacccagtgaatgccccatgtaaaaacaT/CgatgataaaacagcaaagcactgttgtgtgcttgagttgctggacagggatgactcagctaagaagacagcgagagaacctcttagaaatatgcttttattatctgcacacagagatatgactgcctccctctaaagcattactatttgggagagggagtcttgggggGTGATGGGAGGTCCTGAGTC
Sequence 3 (rs760070) 392bp:
TGGATGTCTGCAAAAACCAGaagcggcaaaagcaggtacctgctcacgcccgagactttcacatcaacctctttcaagtgctgccctggctgaaggagaaactccaagatgaggatttgggttttctataaggggtttcctgctggacaggggcgtgggattgaattaaaacagctgcgacaacacctgtgttccagatccttttggggcaagggagtggggaacaggcactggccatgttgttacactgagatcaaacctgacagccgtttttaaaggT/CttaaccccaatcccaagtgctgaaaaaccagaggctgagggagatgtgtaagcttccacctcagtgttttactgagaccagcattggggcatATGAGGCACAAGGAATCCAG
Sequence 4 (rs3880457) 296bp:
ATGAGGCACAAGGAATCCAGctctgttccctagaagccatccacaaggttttccttgtagacgtcatcactgtagacaatctgggtcctcttgtcccggtggcaacccttagggctgttctggacagctagggagggaggagaggaacagttaaggtctaaaggagatcaT/CagaacagaccctgaggctgactcctgaccacctcactcctggccactggcccctggaagcccagtttccacgctgccctctggtggccaggatggcctgtcttccTTAGCTCCTTTGTGCCAACC
Sequence 5 (rs9501161) 356bp:
CCATCCCTTAGGGCAACATAttccaagagctccaatccaaggtggattagaaccacagaatttgtaaaatggagaattcaggagtcgtctaG/AttttttcattttatacatgagaggtgaaactcagaatggtacagcaatttgccagtgcttgagtatgcatatttttccccaaacccatctacattccaacttggagggatgccctttaaacaatctttctgcttgtgctcacctttaacttcccctcaagggttcgagaacgcttgaagcctgagttcttggtctcagccttgatggcactgatggctcctgacttcaccagctgctttgcctgCTCTGTTGCTGTGGCTGTGT
Snapshot primer A (rs429608):
5’-AGCCACTGTACAGCATGGAGCTGGGGAGAAGAGGCCAAGGATTGACTC-3’
Snapshot primer B (rs2075702):
5’-TCTACACCCAGTGAATGCCCCATGTAAAAACA-3’
Snapshot primer C (rs760070):
5’-CTGACAGCCGTTTTTAAAGG-3’
Snapshot primer D (rs3880457):
5’-TCAGCCTCAGGGTCTGTTCT-3’
Snapshot primer E (rs9501161):
5’-ACCACAGAATTTGTAAAATGGAGAATTCAGGAGTCGTCTA-3’
Fig. 1 ~ Fig. 5 is the genotype figure that Snapshot detects rs429608, rs2075702, rs760070, rs3880457 and rs9501161.
The dependency of embodiment 3 SNP site and agedness yellow spot degenerative disease
Statistical method: utilize SPSS13.0 software to analyze, inspection Hardy-Weinberg balance detection, quantitative variation adopts t inspection, and quality variable adopts chi square test.Bilateral P<0.05 thinks statistical significant difference.Result is as follows:
1) essential information of case and contrast
2) SNP site polymorphism and age-related macular degeneration closely related
rs429608：
When not considering age-related macular degeneration tradition risk factor, A allelotrope can improve the resistance of agedness yellow spot degenerative disease, the danger of age-related macular degeneration is significantly reduced (OR=0.51,95%CI=0.35-0.75), and age-related macular degeneration risk reduces by 49%.See Fig. 1.
rs2075702：
When not considering age-related macular degeneration tradition risk factor, C allelotrope can improve the resistance of agedness yellow spot degenerative disease, the danger of age-related macular degeneration is significantly reduced (OR=0.51,95%CI=0.27-0.95), and age-related macular degeneration risk reduces by 49%.See Fig. 2.
rs760070：
When not considering age-related macular degeneration tradition risk factor, C allelotrope can improve the resistance of agedness yellow spot degenerative disease, the danger of age-related macular degeneration is significantly reduced (OR=0.56,95%CI=0.34-0.92), and age-related macular degeneration risk reduces by 44%.See Fig. 3.
rs3880457：
When not considering age-related macular degeneration tradition risk factor, C allelotrope can improve the resistance of agedness yellow spot degenerative disease, the danger of age-related macular degeneration is significantly reduced (OR=0.52,95%CI=0.28-0.96), and namely age-related macular degeneration risk reduces by 48%.See Fig. 4.
rs9501161：
When not considering age-related macular degeneration tradition risk factor, A allelotrope can improve the resistance of agedness yellow spot degenerative disease, the danger of age-related macular degeneration is significantly reduced (OR=0.56,95%CI=0.34-0.90), and namely age-related macular degeneration risk reduces by 44%.See Fig. 5.
Embodiment 4 detection kit
Whole components, content and using method in test kit of the present invention are as follows:
Pcr amplification reagent (50 person-portion):
Sanpshot typing detection reagent (50 person-portion)
Standard DNA sample:
Using method:
1) DNA extraction
Get patient whole blood's (EDTA anti-freezing) 2ml, extract its genomic dna.
2) by the DNA fragmentation of pcr amplification containing the SNP site detected to some extent
Pcr amplification (20 μ l system):
Reaction conditions:
PCR primer detects:
Agarose gel electrophoresis with 2% detects PCR primer, observes the effect of PCR reaction, and determines its amount added in subsequent reactions as template.
3) Sanpshot somatotype detects
The first step: PCR primer purifying (12 μ l system):
Reaction conditions:
1,37 DEG C of enzymes cut 1 hour
2,75 DEG C of deactivations 15 minutes
3,4 DEG C of preservations
Second step: single base primers extension (5 μ l):
Reaction conditions:
3rd step: purification reaction thing:
Reaction system: 0.7 μ l serum alkaline phosphatase/hole
Reaction conditions: 37 DEG C 1 hour, 75 DEG C 15 minutes, 4 DEG C of preservations.
4th step: ABI genetic analyzer reads result:
Reaction system: purified product 1 μ l+HD 9 μ l
Reaction conditions: 95 DEG C 5 minutes, the cooling of rapid ice bath
Machine-readablely on ABI PRISM 3130XL DNA Sequencer get genotype results.
This test kit is used for: 1, the early diagnosis of agedness yellow spot degenerative disease resistance crowd and somatotype reference; 2, the gene test of agedness yellow spot degenerative disease resistance crowd and possibility assessment.
1) detection method of the present invention can be used for the polymorphism analyzing rs429608, rs2075702, rs760070, rs3880457 and rs9501161 five SNP site, is applied in the complementary diagnosis of age-related macular degeneration and the assessment of individual agedness yellow spot degenerative disease resistance.
2) polymorphism in the age-related macular degeneration resistant gene/site utilizing the present invention to set forth, as one of biomarker, can be used as the screening of the molecular target of medicinal design, to help to find the bioactive molecule having and regulate these genetic expressions, promote new drug development.
3) nucleotide sequence of detection SNP site polymorphism set up of the present invention and age-related macular degeneration genes involved/site, can highly sensitive, be applied to the test kit of age-related macular degeneration gene diagnosis specifically.
As mentioned above, reach a conclusion, polymorphism and the age-related macular degeneration of rs429608, rs2075702, rs760070, rs3880457 and rs9501161 five SNP site have significant correlation.Therefore, according to the present invention, measure its polymorphism and can be used for carrying out gene diagnosis.
To sum up, the present invention is by detecting the variation of rs429608, rs2075702, rs760070, rs3880457 and rs9501161 five SNP site, assess the possibility of sample generation agedness yellow spot degenerative disease to be checked, highly sensitive, only need a small amount of DNA sample to be just enough to measure the variation in described site, reach the object of early screening.
Claims (10)
1.5 kinds of variation bases, is characterized in that:
Variation base I is A, is positioned at SKIV2L gene locus rs429608;
Variation base II is C, is positioned at SKIV2L gene locus rs2075702;
Variation base III is C, is positioned at RDBP gene locus rs3880457;
Variation base III is A, is positioned at RDBP gene locus rs9501161.
2. detect SKIV2L gene locus rs429608 variation, site rs2075702 makes a variation, RDBP gene locus rs3880457 makes a variation or/and the purposes of related reagent in the screening agent preparing agedness yellow spot degenerative disease of site rs9501161 variation.
3. purposes according to claim 2, is characterized in that: described reagent comprises detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C makes a variation, RDBP gene locus rs3880457T → C makes a variation or/and the reagent of site rs9501161G → A variation; Also comprise optional SKIV2L gene locus rs429608, site rs2075702, RDBP gene locus rs760070, the site rs3880457 of comprising for increasing or/and the reagent of gene fragment of site rs9501161.
4. purposes according to claim 3, is characterized in that: described detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C variation, RDBP gene locus rs3880457T → C variation are or/and the reagent that site rs9501161G → A makes a variation is Snapshot reagent.
5. purposes according to claim 3, is characterized in that: described detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C variation, RDBP gene locus rs3880457T → C variation are or/and the reagent that site rs9501161G → A makes a variation is order-checking reagent, restriction fragment length polymorphism method reagent or single-strand conformation polymorphism analysis reagent.
6. a kit for screening for agedness yellow spot degenerative disease, is characterized in that: it comprises, and optional for detecting, SKIV2L gene locus rs429608 makes a variation, site rs2075702 makes a variation, RDBP gene locus rs3880457 makes a variation or/and related reagent that site rs9501161 makes a variation.
7. test kit according to claim 6, is characterized in that: described reagent comprises detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C makes a variation, RDBP gene locus rs3880457T → C makes a variation or/and the reagent of site rs9501161G → A variation; Also comprise and optional comprise SKIV2L gene locus rs429608, site rs2075702, RDBP gene locus rs3880457 for increasing or/and the reagent of gene fragment of site rs9501161.
8. test kit according to claim 7, is characterized in that: described detection SKIV2L gene locus rs429608G → A makes a variation, site rs2075702T → C makes a variation, RDBP gene locus rs3880457T → C makes a variation or/and the reagent that site rs9501161G → A makes a variation is Snapshot reagent.
9. test kit according to claim 7, is characterized in that: described detection SKIV2L gene locus rs429608G → A variation, site rs2075702T → C variation, RDBP gene, site rs3880457T → C variation are or/and the reagent that site rs9501161G → A makes a variation is order-checking reagent.
10. test kit according to claim 7, is characterized in that: described detection SKIV2L gene locus rs429608G → A makes a variation, site rs2075702T → C makes a variation, RDBP gene locus rs3880457T → C makes a variation or/and the reagent that site rs9501161G → A makes a variation is restriction fragment length polymorphism method reagent or single-strand conformation polymorphism analysis reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410536200.9A CN104293953A (en) | 2012-05-14 | 2013-05-14 | Screening kit for senile macular degeneration diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210148101.4 | 2012-05-14 | ||
| CN201210148101 | 2012-05-14 | ||
| CN201410536200.9A CN104293953A (en) | 2012-05-14 | 2013-05-14 | Screening kit for senile macular degeneration diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310176231.3A Division CN103215265B (en) | 2012-05-14 | 2013-05-14 | A screening kit for age-related macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104293953A true CN104293953A (en) | 2015-01-21 |
Family
ID=48813424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410536200.9A Pending CN104293953A (en) | 2012-05-14 | 2013-05-14 | Screening kit for senile macular degeneration diseases |
| CN201310176231.3A Active CN103215265B (en) | 2012-05-14 | 2013-05-14 | A screening kit for age-related macular degeneration |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310176231.3A Active CN103215265B (en) | 2012-05-14 | 2013-05-14 | A screening kit for age-related macular degeneration |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN104293953A (en) |
| WO (1) | WO2013170744A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101857899A (en) * | 2009-04-03 | 2010-10-13 | 四川省医学科学院（四川省人民医院） | Kit for detecting senile macular degeneration disease |
| US20110014716A1 (en) * | 2009-07-10 | 2011-01-20 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating macular degeneration |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050266432A1 (en) * | 2004-02-26 | 2005-12-01 | Illumina, Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
-
2013
- 2013-05-14 CN CN201410536200.9A patent/CN104293953A/en active Pending
- 2013-05-14 CN CN201310176231.3A patent/CN103215265B/en active Active
- 2013-05-14 WO PCT/CN2013/075618 patent/WO2013170744A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101857899A (en) * | 2009-04-03 | 2010-10-13 | 四川省医学科学院（四川省人民医院） | Kit for detecting senile macular degeneration disease |
| US20110014716A1 (en) * | 2009-07-10 | 2011-01-20 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating macular degeneration |
Non-Patent Citations (2)
| Title |
|---|
| BROOK ALLISON CATTELL LONGVILL: "Genetic Epidemiology of Age-Related Macular Degeneration(AMD):The Role of the Complement Component2(C2) and Complement Factor B(CFB) Genes in Determining AMD Subphenotypes", 《MURDOCH UNIVERSITY LIBRARY RESEARCH REPOSITORY》, 31 December 2010 (2010-12-31), pages 1 - 295 * |
| NAOSHI KONDO ET AL.: "Role of RDBP and SKIV2L Variants in the Major Histocompatibility Complex Class III Region in Polypoidal Choroidal Vasculopathy Etiology", 《OPHTHALMOLOGY》, vol. 116, no. 8, 31 August 2009 (2009-08-31), pages 1502 - 1509, XP026419692 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103215265B (en) | 2015-02-18 |
| WO2013170744A1 (en) | 2013-11-21 |
| CN103215265A (en) | 2013-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105400868A (en) | Methods Of Using Mirna For Detection Of In Vivo Cell Death | |
| CN102220413B (en) | Method for detecting exon 19 deletion mutation and exon 21 point mutation of epidermal growth factor receptor gene | |
| CN105543361A (en) | DNA library for detecting and diagnosing polycystic kidney pathogenic gene and application thereof | |
| CN101892306B (en) | Screening test kit for detecting pathologic moyopia | |
| CN102251045B (en) | Screening kit for detecting high myopia | |
| CN101812537A (en) | Method and reagent kit for simultaneously detecting resistance site of three nucleotide analogues of hepatitis B virus | |
| BR112021015845A2 (en) | SALIVARY BRAIN INJURY BIOMARKERS | |
| EP2702174B1 (en) | System for identification of micro-organisms and detection of infectious disorders | |
| CN105331623A (en) | MTB (mycobacterium tuberculosis) rpoB mutant gene and application thereof | |
| CN107312867B (en) | Diagnose SNP and its application of hypothyroidism | |
| CN104293953A (en) | Screening kit for senile macular degeneration diseases | |
| CN108823303A (en) | A kind of detection kit and its purposes for assessing schizophrenia genetic risk | |
| CN106755461B (en) | Interleukin-21 associated with primary biliary cholangitis and its application | |
| CN105112415A (en) | Genetic locus rs780092 for evaluating type 2 diabetes mellitus risk and detection kit | |
| CN107686861A (en) | ERBB2 R113Q mutators are used to prepare the application for judging mammary gland genetic susceptibility of cancer kit | |
| CN102676661B (en) | Fluorescent polarization based homogeneous phase detection method of single nucleotide polymorphism of codon118 of ERCC1 (excision repair cross-complementing 1) gene | |
| CN102618650B (en) | Kit for detecting people's life | |
| CN107385076B (en) | A kind of hypothyroidism Disease-causing gene mutation and the diagnostic reagent based on this gene mutation | |
| CN113215248A (en) | MyO15A gene mutation detection kit related to sensorineural deafness | |
| CN103266181B (en) | Kit for detecting transthyretin (TTR) gene mutant G307C | |
| CN110317876A (en) | Application of the unstable variation of one group chromosome in preparation diagnosis Huppert's disease, the reagent or kit of assessing prognosis | |
| CN108753970A (en) | Nonfunctioning pituitary adenoma detection device and application | |
| CN101586165A (en) | Kit for detecting 2975-2978delAG mutation of OTOF gene | |
| CN100368564C (en) | A primer, method and kit for identifying PGC-1 gene promoter-1998 SNP molecular marker | |
| CN106222253B (en) | Detection kit for age-related macular degeneration choroidal polypoid vascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150121 |